[go: up one dir, main page]

WO2006048263A3 - Profilage de l'expression genique dans la leucemie promyelocytique aigue - Google Patents

Profilage de l'expression genique dans la leucemie promyelocytique aigue Download PDF

Info

Publication number
WO2006048263A3
WO2006048263A3 PCT/EP2005/011729 EP2005011729W WO2006048263A3 WO 2006048263 A3 WO2006048263 A3 WO 2006048263A3 EP 2005011729 W EP2005011729 W EP 2005011729W WO 2006048263 A3 WO2006048263 A3 WO 2006048263A3
Authority
WO
WIPO (PCT)
Prior art keywords
leukemia
apl
acute promyelocytic
treatment
promyelocytic leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/011729
Other languages
English (en)
Other versions
WO2006048263A2 (fr
Inventor
Torsten Haferlach
Martin Dugas
Wolfgang Kern
Alexander Kohlmann
Susanne Schnittger
Claudia Schoch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Original Assignee
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Roche Diagnostics GmbH filed Critical F Hoffmann La Roche AG
Publication of WO2006048263A2 publication Critical patent/WO2006048263A2/fr
Publication of WO2006048263A3 publication Critical patent/WO2006048263A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Data Mining & Analysis (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Databases & Information Systems (AREA)
  • Public Health (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Signal Processing (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des approches rapides et fiables concernant la détection et le sous-typage de la leucémie. Selon certains aspects, par exemple, la présente invention porte sur la LPA qui devrait généralement être détectée rapidement et de manière extrêmement sure, étant donné qu'en comparaison aux autres LPA, ainsi qu'aux autres leucémies, la LPA nécessite typiquement un traitement spécifique et unique en son genre, tel qu'un premier traitement avec de l'acide rétinoïque au lieu de la chimiothérapie. Etant donné que deux sous-types de LPA peuvent apparaître morphologiquement et que ces deux sous-types nécessitent ce traitement, ils devraient être détectés sans équivoque et distingués de tous les autres sous-types de LPA et des autres leucémies. La présente invention concerne non seulement des méthodes, mais également des kits et des systèmes.
PCT/EP2005/011729 2004-11-04 2005-11-03 Profilage de l'expression genique dans la leucemie promyelocytique aigue Ceased WO2006048263A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62568504P 2004-11-04 2004-11-04
US60/625,685 2004-11-04

Publications (2)

Publication Number Publication Date
WO2006048263A2 WO2006048263A2 (fr) 2006-05-11
WO2006048263A3 true WO2006048263A3 (fr) 2007-04-12

Family

ID=36319538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/011729 Ceased WO2006048263A2 (fr) 2004-11-04 2005-11-03 Profilage de l'expression genique dans la leucemie promyelocytique aigue

Country Status (1)

Country Link
WO (1) WO2006048263A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106951710A (zh) * 2017-03-22 2017-07-14 华东师范大学 基于特权信息学习支持向量机的cap数据系统及方法
CN107974506A (zh) * 2018-01-17 2018-05-01 华中科技大学鄂州工业技术研究院 一种用于急性髓系白血病药物指示的方法及装置

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
CN103074422A (zh) * 2012-12-29 2013-05-01 深圳市第三人民医院 Ms4a6a基因的用途
EP3004395A4 (fr) * 2013-06-05 2017-01-04 Merck Sharp & Dohme Corp. Compositions et méthodes pour le traitement du cancer
CN111424083A (zh) * 2019-01-10 2020-07-17 北京医院 一种白血病标志物及其在白血病预后评估中的用途
CN112763474B (zh) * 2020-12-23 2022-05-06 中国医学科学院血液病医院(中国医学科学院血液学研究所) 一种预测或检测急性白血病的生物标志物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000191547A (ja) * 1998-12-28 2000-07-11 Agency Of Ind Science & Technol 白血病細胞の増殖阻害剤及び凝集剤並びにそれを用いた凝集方法
WO2003039443A2 (fr) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Nouveaux marqueurs genetiques pour leucemies
WO2005080601A2 (fr) * 2004-02-23 2005-09-01 Erasmus Universiteit Rotterdam Classification, diagnostic, et pronostic de leucemie myeloide par profilage de l'expression genique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000191547A (ja) * 1998-12-28 2000-07-11 Agency Of Ind Science & Technol 白血病細胞の増殖阻害剤及び凝集剤並びにそれを用いた凝集方法
WO2003039443A2 (fr) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Nouveaux marqueurs genetiques pour leucemies
WO2005080601A2 (fr) * 2004-02-23 2005-09-01 Erasmus Universiteit Rotterdam Classification, diagnostic, et pronostic de leucemie myeloide par profilage de l'expression genique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 2000-551659, XP002399063, "leukemic cell proliferation inhibitor for treating blood cancer comprises agrin" *
GUTIERREZ NORMA C ET AL: "Acute Promyelocytic Leukemias and Monocytic Leukemias Show an Specific Gene Expression Profile Different from Other AML.", BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), & 44TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; PHILADELPHIA, PA, USA; DECEMBER 06-10, 2002, pages Abstract No. 2173, XP009072314, ISSN: 0006-4971 *
HAFERLACH T ET AL: "The Diagnosis of 14 Specific Subtypes of Leukemia Is Possible Based on Gene Expression Profiles: A Study on 263 Patients with AML, ALL, CML, or CLL", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 100, no. 11, 16 November 2002 (2002-11-16), pages 139A, XP002263227, ISSN: 0006-4971 *
KOHLMANN A ET AL: "MOLECULAR CHARACTERIZATION OF ACUTE LEUKEMIAS BY USE OF MICROARRAY TECHNOLOGY", GENES, CHROMOSOMES & CANCER, XX, XX, vol. 37, no. 4, August 2003 (2003-08-01), pages 396 - 405, XP008025253 *
PAIETTA ELISABETH: "Expression of cell-surface antigens in acute promyelocytic leukaemia.", BEST PRACTICE & RESEARCH. CLINICAL HAEMATOLOGY. SEP 2003, vol. 16, no. 3, September 2003 (2003-09-01), pages 369 - 385, XP002399060, ISSN: 1521-6926 *
SCHOCH CLAUDIA ET AL: "Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 99, no. 15, 23 July 2002 (2002-07-23), pages 10008 - 10013, XP002215484, ISSN: 0027-8424 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106951710A (zh) * 2017-03-22 2017-07-14 华东师范大学 基于特权信息学习支持向量机的cap数据系统及方法
CN107974506A (zh) * 2018-01-17 2018-05-01 华中科技大学鄂州工业技术研究院 一种用于急性髓系白血病药物指示的方法及装置
CN108130372A (zh) * 2018-01-17 2018-06-08 华中科技大学鄂州工业技术研究院 一种用于急性髓系白血病药物指示的方法及装置
CN108277278A (zh) * 2018-01-17 2018-07-13 华中科技大学鄂州工业技术研究院 一种用于正常核型急性髓系白血病预后分层的方法及装置

Also Published As

Publication number Publication date
WO2006048263A2 (fr) 2006-05-11

Similar Documents

Publication Publication Date Title
WO2007044763A3 (fr) Systeme et procede permettant la detection de transactions frauduleuses
WO2008011519A3 (fr) Inhibiteurs d'amigo-2 pour le traitement, le diagnostic ou la détection du cancer
WO2007092009A3 (fr) Système et procédé de dépôt, de détection et d'identification d'agents de menace
USD931321S1 (en) Electronic whiteboard with graphical user interface
TW200718259A (en) Removing time delays in signal paths
WO2008099241A3 (fr) Informations météorologiques sur un calendrier
WO2008070269A3 (fr) Procédés, logiciel et systèmes d'imagerie
WO2006076253A3 (fr) Systeme de traitement au plasma et ensemble deflecteur destine a etre utilise dans ce systeme de traitement au plasma
WO2005123277A3 (fr) Films optiques et leurs procedes de production
WO2008144964A8 (fr) Détection d'entités de nom et nouveaux mots
WO2008011170A3 (fr) Procédé pour détecter la présence de répétitions étendues de cgg dans la région non traduite en 5' du gène fmr1
WO2007100527A3 (fr) Procédé et système permettant d'effectuer des transactions informatisées
USD914735S1 (en) Electronic whiteboard with graphical user interface
WO2010009060A3 (fr) Procédés par balise moléculaire pour la détection de cibles utilisant l'abscription
MX2009005058A (es) Metodos para tratar, diagnosticar o detectar cancer.
WO2005101112A3 (fr) Films optiques et procedes de fabrication de ces derniers
WO2008005798A3 (fr) Traitement de données sismiques
WO2004094667A3 (fr) Reactifs et methodes permettant de detecter le coronavirus responsable du syndrome respiratoire aigu severe
WO2006048263A3 (fr) Profilage de l'expression genique dans la leucemie promyelocytique aigue
WO2006065597A3 (fr) Complexes, reseaux d'etiquettes d'identite et procedes d'utilisation afferents
MY141863A (en) Plastisols based on a methyl methacrylate copolymer
EP1811023A4 (fr) Gene exprime specifiquement dans les cellules es et utilisation dudit gene
USD914736S1 (en) Electronic whiteboard with graphical user interface
EP1566448A3 (fr) Diagnose différentielle avec la hepcidine
WO2006048264A3 (fr) Etablissement de profils de l'expression genique de la leucemie lymphoblastique aigue (all), la leucemie aigue biphenotypique (bal) et la leucemie myeloide aigue (aml) m0

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05807569

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 05807569

Country of ref document: EP

Kind code of ref document: A2